Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

NCT00617656 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

382

Enrollment

OTHER

Sponsor class

Stopped No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental arm over the control arm- would not be confirmed.

Conditions

Non Small Cell Lung Cancer
BRCA1 Mutation

Interventions

DRUG: Cisplatin, Docetaxel
DRUG: Gemcitabine, Cisplatin
DRUG: Docetaxel, Cisplatin
DRUG: Docetaxel

Sponsor

Spanish Lung Cancer Group